BTIG Virtual Biotechnology Conference
BTIG hosted the “BTIG Virtual Biotechnology Conference” on Monday, August 10, 2020 and Tuesday, August 11, 2020. BTIG Biotechnology Analysts Dae Gon Ha, PhD, Julian Harrison, Robert “Bert” Hazlett and Thomas Shrader, PhD, CFA, hosted the conference in addition to BTIG Healthcare Strategy and Franchise Sales Specialists Mikhail Keyserman, CMT, CFTe, and Michael Karmiol. The firm’s virtual, private event consisted of thematic panels, fireside chats with company management and one-on-one meetings.
Some of the topics for discussion included:
- Solid Tumors: Are Cell, ADCs or Bi-mAbs the Next Frontier?
- Immuno-oncology: Are We Closing in on Post PD1 Regimens?
- Advances in Neurosciences: Are there Useful Biomarkers?
- NASH: Does a Backbone Drug Need to Do More Than Control Lipids?
- KRAS Inhibition in Solid Tumors – Material Advancements and Continuing Challenges
For more information about the conference, email [email protected]. Please note that participants must be pre-registered to attend.
This information was prepared for BTIG, LLC institutional clients. The information contained herein has been gathered from multiple sources and is believed to be reliable. However, BTIG, LLC has not independently verified the accuracy of the content and does not make any representations as to the accuracy or completeness of this information. The information is subject to change without notice and BTIG, LLC has no obligation to provide any updates or changes. BTIG, LLC is providing this data for informational purposes and does not believe that it is sufficient to base an investment decision on. This information should not be regarded as a solicitation or recommendation of any particular security or to engage in any trading strategy. BTIG, LLC does and may seek to do business, including investment banking and/or other capital markets business, with companies which are the subject of Corporate Access services.